QLT Inc.

218 articles with QLT Inc.

• QLT Inc. Announces First Patient Dosed In Phase 2a Proof-Of-Concept Trial For QLT091001 In Impaired Dark Adaptation

  12/9/2013

• QLT Inc. Announces Oral Retinoid Program Clinical And Regulatory Update, And Review Of Strategic Alternatives

  11/21/2013

• QLT Inc. Announces Third Quarter 2013 Results

  11/7/2013

• QLT Inc. Announces Second Quarter 2013 Results

  8/1/2013

• QLT Inc. Announces Completion of US$200 Million Special Cash Distribution to Shareholders

  6/28/2013

• QLT Inc. Board Issues Letter to Shareholders Announcing Corporate Progress and 2013 Objectives

  1/28/2013

• QLT Inc. Announces Exclusive Option Agreement for Potential Sale of Punctal Plug Delivery System

  12/27/2012

• QLT Inc. Cuts Workforce by 42 Percent

  12/6/2012

• QLT Inc. Announces Third Quarter 2012 Results

  11/7/2012

• QLT Inc. Shows Positive Efficacy Trends From Data in Plug Combinations in Phase II Studies for Glaucoma Using Latanoprost Punctal Plug Delivery System

  10/25/2012

• QLT Inc. Announces Share Repurchase Program

  9/27/2012

• Valeant Pharmaceuticals International Buys QLT Inc.'s Eye Treatment Visudyne for $112.5 Million

  9/24/2012

• QLT Inc. Announces Second Quarter 2012 Results

  8/2/2012

• QLT Inc. Slashes Workforce by Two-thirds, CEO Quits After Shareholder Coup

  7/10/2012

• QLT Inc. Announces Results of 2012 Annual Meeting of Shareholders

  6/5/2012

• QLT Inc. Affirms Commitment to Return Capital to Shareholders

  5/31/2012

• QLT Inc. Highlights Strategic Initiatives to Enhance Shareholder Value

  5/25/2012

• QLT Inc. Postpones Annual General Meeting of Shareholders

  5/24/2012

• QLT Inc. Responds With an Open Letter to Stockholders

  5/23/2012

• QLT Inc. Announces Notification of Legal Proxy Action in Advance of Annual Meeting of Stockholders

  5/23/2012